Protein kinases play important regulatory roles in cells and organisms. Therefore, they are subject to specific and tight mechanisms of regulation that ultimately converge on the catalytic domain and allow the kinases to be activated or inhibited only upon the appropriate stimuli. AGC protein kinases have a pocket in the catalytic domain, the PDK1-interacting fragment (PIF)-pocket, which is a key mediator of the activation. We show here that helix aC within the PIF-pocket of atypical protein kinase C (aPKC) is the target of the interaction with its inhibitory N-terminal domains. We also provide structural evidence that the small compound PS315 is an allosteric inhibitor that binds to the PIF-pocket of aPKC. PS315 exploits the physiological dynamics of helix aC for its binding and allosteric inhibition. The results will support research on allosteric mechanisms and selective drug development efforts against PKC isoforms.
INTRODUCTION
Cellular functions are regulated by numerous signaling mechanisms. Many of these regulatory mechanisms ultimately rely on conformational changes in the proteins that transfer information through signaling cascades to the effector molecules. Protein kinases, intermediate signaling molecules, are tightly regulated by activating and inhibitory mechanisms that allosterically converge on the catalytic domain (Huse and Kuriyan, 2002; Pawson and Scott, 2005) . The overall structure of the catalytic domain is highly conserved throughout the protein kinase family. It consists of a bilobal domain with a small lobe and a large lobe ( Figure 1A) , with the ATP-binding site situated between the two lobes and the substrate peptide-binding site mostly located on the large lobe (Knighton et al., 1991) .
AGC kinases (a group of protein kinases comprising the protein kinase A (PKA), protein kinase G, and protein kinase C (PKC) families) typically have three conserved phosphorylation sites (Newton, 2010; Parker and Parkinson, 2001; Vanhaesebroeck and Alessi, 2000) . The first is located in the activation loop and, when phosphorylated, links the small and large lobes of the kinase domain, closing the structure and stabilizing the active conformation. The other two conserved phosphorylation sites are located in the region C-terminal to the kinase domain. The turn motif (also termed ''zipper'') and the hydrophobic motif (HM) phosphorylation sites, when phosphorylated, allow the interaction of the C terminus with phosphate-binding sites on the small lobe and support the binding of the HM (Phe-XaaXaa-Phe, Figure 1A ) to the PDK1-interacting fragment (PIF)-pocket located on the small lobe between the aC helix and b sheets 4 and 5 (Arencibia et al., 2013; Hauge et al., 2007) .
The PIF-pocket of 3-phosphoinositide-dependent protein kinase 1 (PDK1) allows for substrate docking (Biondi et al., 2001) and allosteric stimulation of kinase activity ). The equivalent PIF-pocket site in other AGC kinase families, such as S6K, serum-and glucocorticoidstimulated kinase, protein kinase B (PKB)/Akt, p90 ribosomal S6 kinase, and mitogen-and stress-activated protein kinase, is critical for activation by HM phosphorylation (Frö din et al., 2002; Yang et al., 2002) . Phosphorylation of the HM (Phe-XaaXaa-Phe-Ser/Thr-Tyr/Phe) triggers the intramolecular interaction of the HM, with the Phe residues docking into the hydrophobic PIF-pocket. Indeed, the crystal structures of active AGC kinases reveal that the Phe residues of the HM bind to the PIF-pocket (Pearce et al., 2010) . The key function of this particular pocket was confirmed by the development of small molecules that bind to the PIF-pocket of PDK1 and, thereby, activate the kinase in vitro (Engel et al., 2006; Wei et al., 2010) , stabilizing local and allosteric conformational changes that mimic the effects of phosphorylation .
Members of the protein kinase C (PKC) family are regulated by phosphorylation and by an N-terminal extension of the catalytic domain (Newton, 2010) . All PKCs contain a pseudosubstrate region (PSR) and a contiguous C1 domain. Conventional PKCs have two C1 domains and one C2 domain, novel PKCs possess two C1 domains and one novel C2 domain, and atypical PKCs (aPKCs) contain a PSR that is connected to a single atypical C1 domain (see Figure 1B) . It is thought that the PSR binds substrate-like (pseudosubstrate) to the peptide-substrate binding site of PKCs and that this inhibition is released by the binding of second messengers, such as Ca 2+ and diacylglycerol, to the C1 and C2 domains of conventional PKCs. More recently, we identified that the C1 domain of the atypical PKCz isoform also plays a key role in the inhibition of the activity, acting together, as a block, with the pseudosubstrate . Atypical PKC isoforms play an important role in cellular polarization. A splice variant of PKCz, protein kinase M (PKM) z, which lacks the N-terminal regulatory regions, is expressed in neurons and is necessary for long-term memory and longterm potentiation and participates in chronic pain (Price and Ghosh, 2013) . On the other hand, the PKCi isoform has been more widely validated as a drug target for cancers (Atwood et al., 2013; Murray et al., 2011 ).
Here we identify helix aC as a key mediator of aPKC mechanism of inhibition by the N-terminal domains and determine that the PIF-pocket is a specific binding site for small compounds that allosterically inhibit aPKCs. We conclude that the PIF-pocket has evolved as a critical mediator of the regulation of AGC kinases by transducing signals from second messengers and posttranslational modifications into conformational changes that either activate or inhibit the target kinase. Notably, this work provides structural and molecular information for the development of small allosteric compounds that modulate the conformation of signaling molecules, thereby aiding future drug development efforts toward targeting allosteric proteins.
RESULTS

The N-terminal Domains Protect Two Regions of the PKCi Catalytic Domain
To study the inhibitory effects of the N-terminal extension of PKCi on its catalytic domain, we expressed purified and biochemically characterized full-length and truncated catalytic domain constructs of PKCz and PKCi ( Figure 1B ; Figure S1 available online). We selected PKCi for further studies because this isoform could be obtained in higher homogeneity, was monomeric, and was stable under the experimental conditions required. To analyze the dynamic of the proteins in solution, we made use of the ability of backbone amide hydrogens to be exchanged for deuteriums, depending on their exposure to the deuterated solvent. For hydrogen/deuterium ( 1 H/ 2 H) exchange experiments, PKCi 1-587 and PKCi D223 ( Figure 1B ) were incubated for various times in a buffer containing 2 H 2 O. Subsequently, the isotopic exchange was quenched by acidification, the protein was subjected to proteolysis, and the polypeptides corresponding to the catalytic domain were analyzed by mass spectroscopy. We identified 81% common polypeptides from the catalytic domain, which we then used for the comparisons ( Figure S2 [233] [234] [235] [236] [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [261] [262] [263] [264] [265] [266] [267] [268] [269] [270] [271] [272] [273] Figure S3) , indicating that they were not affected by the presence of the N-terminal region. However, a significant protection was observed in overlapping polypeptides from the catalytic domain that corresponded to two distinct regions: region 1, located at the interphase between the small and large lobes and encompassing amino acid sequences from helix aC, helix aE, and the DFG motif (DYG in PKCi), and region 2, located on the large lobe and encompassing sequences from the P+1 loop and part of helix aF (Figure 2 ). Within region 1 of PKCi D223, a 20-amino acid polypeptide comprising the entire helix aC (286-306, Figure 2C ) and five residues from the following loop exchanged 12 1 H for 2 H (12 out of an experimental maximum of 14.9) after a 10 s incubation, indicating that the region is highly exposed to solvent. Only a single additional 1 H was exchanged for 2 H after prolonging the incubation time to 166 min. Importantly, the same polypeptide derived from the full-length protein exchanged fewer than 4 1 H for 2 H at the first time point, indicative of a protection of more than 8 1 H. Although this region was highly protected, we conclude that it retained some degree of flexibility in the full-length protein because the protection was completely lost after 166 min of incubation. This protection was observed in PKCi 1-587 in overlapping polypeptides [290] [291] [292] [293] [294] [295] [296] [297] [298] [299] [300] [301] [302] [303] , suggesting that amino acids 286-308 afforded the majority of the protection. A second protected amino acid sequence in the full-length protein comprised residues 355-370 ( Figures 2F-2H ), corresponding to the end of helix aE and the following loop region on the large lobe below helix aC (Figure 2A ). In this case, two overlapping polypeptides provided evidence for the protection of 2-3 1 H after 166 min of incubation in the deuterated solution. Another sequence with low but reproducible protection from 1 H/ 2 H exchange corresponded to polypeptide 376-390 ( Figure 2I ) and its overlapping polypeptide 382-390 ( Figure 2J ), corresponding to a region that links helix aC and the ATP-binding site and contains the DFG/ DYG motif. Finally, a second protected region (region 2) was identified via the distinct 1 H/ 2 H exchange of a series of polypeptides comprising residues 405-448, which contains the end of the activation loop, the P+1 loop (405) (406) (407) (408) (409) (410) (411) (412) (413) (414) (415) (416) Figures 2K and 2L) , and helix aF (417-434 and 435-445, Figures 2M and 2N ), all of which are situated on the front of the large lobe ( Figure 2A) .
Together, the results indicated that the N-terminal domains of PKCi protected the catalytic domain from 1 H/ 2 H exchange in two distinct regions, one centered on helix aC and the other corresponding to the peptide-substrate binding region in protein kinases.
Identification of the PKCi Region Protected by the PSR
The PSR and the C1 domain are adjacent within the N terminus of conventional, novel, and atypical PKCs ( Figure 1B ). The PSR was thought to be the sole determinant of the intramolecular inhibition of PKC isoforms. However, we recently determined that both the PSR and the C1 domain act together to inhibit and activate aPKCs , corresponding with a model where the PSR provides the highest affinity to the intramolecular interaction. To probe the specific effect of the PSR on the catalytic domain, we preincubated PKCi 1-587 and PKCi D223 with PSRtide (KSIYRRGARRWRKLYRA), a polypeptide derived from the PSR, and subjected the samples to a time course of 1 H/ 2 H exchange, followed by standard 1 H/ 2 H exchange analysis.
The incubation of PKCi 1-587 (57 mM) with a 20-, 10-, or 5-fold higher concentration of PSRtide triggered the precipitation of the protein, thereby precluding further analysis. The precipitation of concentrated PKCi 1-587 after the addition of PSRtide indicated that the binding of PSR to full-length PKCi 1-587 decreased its stability in solution. On the other hand, we obtained high-quality 1 H/ 2 H exchange data after preincubating PKCi D223 with PSRtide ( Figure 3) . Most of the polypeptides mapping to the catalytic domain of PKCi did not exhibit differences in the 1 H/ 2 H exchange rate in the presence or absence of PSRtide. Notably, we observed that PSRtide significantly protected polypeptides [405] [406] [407] [408] [409] [410] [411] [412] [413] [414] [415] [416] that correspond to region 2 but not of region 1 polypeptides (Figures 3B-3J ). The region 2 sequence is equivalent to a region in PKA that interacts with the last seven amino acids of the pseudosubstrate inhibitor protein kinase inhibitor, as observed in the crystal structure of PKA in complex with ATP and protein kinase inhibitor (Zheng et al., 1993) . Therefore, the protection of these region 2 polypeptides supports the hypothesis that the PSR interacts with the substrate-binding site in PKCs. This is in further 
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Mechanism of Allosteric Inhibition of aPKC agreement with PSRtide inhibiting PKCi D223 in a substratecompetitive manner ( Figure S4A ) and with reports that show that z inhibitory particle, the myristylated form of PSRtide, is a high-affinity, substrate-competitive inhibitor of PKMz (K d = 78 nM) (Yao et al., 2013) . Importantly, the data also indicate that the PSR does not directly or allosterically protect other regions of the PKCi catalytic domain. Interestingly, neither the magnitude nor the kinetics of the protection were similar to those produced by the complete N-terminal region of PKCi, indicating that other N-terminal regions were responsible for the enhanced protection observed on overlapping peptides within residues 405-448. The C terminus of the PSR is connected directly to the C1 domain, and our previous data indicated that it directly interacted with the catalytic domain. When the PSR binds like a substrate, the C1 domain is expected to be located to make direct contact with the aC and aE helices. Together, the data presented here support the contention that the extended protection observed in region 1 (Figure 2A ) is due to direct interaction of the C1 domain with the aC helix. However, the low affinity of the catalytic domain to the isolated C1 domain does not allow us to experimentally test this interaction in parallel using 1 D223 produced distinct fluorescence emission curves, indicating that they differ in their unfolding patterns. The thermal stability curves for PKCi 1-587 were more complex than those produced by PKCi D223 (Figure S4B ), which was expected because PKCi 1-587 is a multidomain protein. We evaluated the thermal shift and the effect of additives on the thermal stability of the PKCi constructs. As a control, we tested the effect of the nonspecific ATP-competitive inhibitor staurosporine on the stability of PKCi 1-587 and PKCi D223. Staurosporine induced an 8 C increase in the thermal stability of both proteins, suggesting that the domains N-terminal to the catalytic domain do not cooperate with the ATP-binding site to provide additional stability ( Figure 4A ).
In the established stability assay, an excess of PSRtide increased the melting temperature of PKCi D223 by 3 C. In contrast, under the same conditions, PKCi 1-587 was destabilized by PSRtide by approximately 4 C ( Figure 4A ). This difference corresponds with the destabilizing effect of PSRtide on PKCi 1-587 observed in the 1 H/ 2 H exchange experiments. We hypothesize that the stability provided by the binding of PSRtide to the catalytic domain of PKCi 1-587 is negated by the decrease in stability stemming from the concomitant displacement of other N-terminal regions. The effect is compatible with a model where, when PKCi 1-587 is in the inactive state, the C1 domain is responsible for the large interaction surface observed in region 1 when the contiguous PSR is correctly positioned at the substrate-binding site. The displacement of the PSR upon the addition of PSRtide reduces the interaction of the C1 domain with the catalytic domain.
Mechanism of Inhibition by Allosteric PIF-pocket Binding Compounds
Throughout the years, we built a focused library of compounds directed to the PIF-pocket of AGC kinases. The original compounds were obtained by in silico screening for compounds predicted to bind to the PIF-pocket of the active structure of PKA and were characterized as allosteric activators of PDK1 (Engel et al., 2006) . Follow-up compounds in the library were designed based on the initial hits and by scaffold hopping, keeping a fixed angle between the two main ring systems to occupy the two subpockets present in the PIF-pocket of active AGC kinases. Upon investigating the effect of the compounds on different AGC kinases, we completed our library by synthesizing variants from activators and inhibitors (i.e., Frö hner et al., 2011; Wilhelm et al., 2012) . By screening our focused compound library for the ability to inhibit PKCz D241 activity, we identified a small molecule, PS315 ( Figure 4C ), that inhibited the isolated catalytic domains of PKCz and PKCi equally in vitro. PS315 was derived from PS48 ( Figure 4C ,) ), which did not affect the activity of aPKCs in vitro. In U937 cells, PKCz is required for tumor necrosis factor-a (TNF-a)-induced NF-kB activation (Levy et al., 2011; Mü ller et al., 1995) . We therefore employed a luciferase reporter of NF-kB activation in U937 cells to screen the effect of different active compounds in a cellular setting, as we performed previously . Preincubation of U937 cells with 5 mM PS315 inhibited TNF-a induced NF-kB activation by 74%, whereas complete inhibition was observed with 10 mM PS315 ( Figure S5 ). Because PS315 was cell-permeable and gave consistent results in a cell culture model system, we selected PS315 to investigate the mechanism of inhibition of aPKCs in vitro. PS315 inhibited all constructs of aPKCs tested ( Figure 4D ). In vitro, PS315 inhibited the full-length and catalytic domain constructs of PKCz (half maximal inhibitory concentration (IC 50 ) = 10 mM) and PKCi (IC 50 = 30 mM, Figure 4E ). PS315 is a derivative of PS48, a compound that we showed previously to bind to the PIF-pocket and activate protein kinase PDK1 . Therefore, we investigated whether PS315 produced the inhibition by interaction with the PIF-pocket of aPKCs. PS315 did not increase the thermal stability of PKCi 1-587 or PKCi D223. Instead, it decreased the thermal stability of both PKCi constructs with a more significant destabilization of the full-length PKCi construct ( Figure 4B ). This was distinct from the primarily stabilizing effect of staurosporine, which inhibits kinases by occupying the ATP-binding site. To control for selectivity, we determined that PS314, a diastereomer of PS315, did not alter the stability of PKCi.
Crystal Structure of Allosteric Compound PS315 in Complex with a PDK1/PKCz Chimera To provide more conclusive evidence for the PS315 binding site and to study its mechanism of inhibition, we attempted to crystallize PS315 in complex with PKCz and PKCi, although without success. In our previous studies on PDK1 and PS48, we obtained crystals of the complex only after mutating two residues in helix aG (Tyr288Gly and Gln292Ala) of PDK1 50-359 ). The double mutant protein (dmPDK1 50-359) crystallized in a novel crystal packing (crystal packing II) that allowed for both cocrystallization with and soaking of PS48 into the PIFpocket. The small conformational changes observed did not disturb the crystal. We also mutated eight residues within the PIF-binding pocket of GST-PDK1 1-556 to mimic the PIF-pocket of PKCz, producing a protein chimera that was inhibited by PS168 . Similarly, we introduced the eight mutations in the PIF-pocket of dmPDK1 50-359 ( Figure 5A ). The resulting chimera (dmPDK1-z) was inhibited by PS168 (Figure 4F) . Furthermore, although dmPDK1 50-359 was not affected by 100 mM PS315, dmPDK1-z was inhibited by 50% ( Figure 4D ). Interestingly, PS48 activated dmPDK1 50-359 but had no effect on dmPDK1-z, suggesting that the mutations in the PIF-pocket of dmPDK1 50-359 altered the selectivity of the PIF-pocket and its specific effects on the activity from PDK1 to that of aPKCs. Most notably, dmPDK1-z crystallized in crystal packing II, and the structure of this protein in complex with PS315 was obtained. The structures of dmPDK1-z (1.35 Å resolution; R factor, 0.20; R free , 0.21) and dmPDK1-z/PS315 (1.9 Å resolution; R factor 0.18; R free , 0.22; Tables S1 and S2) were solved by molecular replacement based on the structure of dmPDK1 code 3HRF; ). The crystal structure of the complex revealed that PS315 is bound in the PIF-pocket of the dmPDK1 50-359-z chimera ( Figures 5C, 5E , and 5F), therefore establishing the PIF-pocket as the allosteric binding site of PS315. The dmPDK1-z structure showed very weak and intermittent electron (F) Superimposition of the structures of PS48-bound dmPDK1 (purple) and PS315-bound dmPDK1-z (pink) with focus on the interface between the active site and the tunnel to the PIF-pocket. Compound PS315 causes the εÀamino group of Lys111 to be unresolved and to lose its salt bridges with Glu130 and the a-phosphate of ATP. Furthermore, conformational changes of Ser92 and Phe93 in the Gly-rich loop were observed. density for helix aB and the loop between aB and aC of the PIF pocket. Thus, this region could not be modeled reliably. Notably, this region was well resolved and, thus, stabilized in the PS315-bound structure. Strong and unambiguous electron density was observed for the biphenyl and carboxylate moieties of PS315. A weaker density was obtained for the p-chlorophenyl group in the shallow part of the PIF-pocket.
Previously published crystal structures of PKCi demonstrated that the HM, which is located within the C-terminal extension of the catalytic core, binds to the PIF-pocket (Messerschmidt et al., 2005; Takimura et al., 2010) . Therefore, the binding of PS315 to the same site must induce a displacement of the C-terminal region from its position. Thus, the inhibition of PKCi by PS315 might be due to a loss of activation by the displacement of the C-terminal region that results from the movement of the HM away from its binding site by PS315. To test this possibility, we expressed a mutant form of PKCi D223 lacking the last 31 amino acids (PKCi D223 DHM, Figure 1B ). PKCi D223 DHM was active and inhibited by PS315 ( Figure 6A ). Therefore, the data indicated that inhibition by PS315 was not mediated by the displacement of the HM of PKCi from its binding site in the PIF-pocket. In addition, our data show that PS315 inhibited PKCi D223 DHM better than PKCi D223 ( Figure 6A ), suggesting that, when the HM is not bound to the PIF-pocket, PS315 has an increased ability to bind and inhibit PKCi. Interestingly, the data further suggest that PKCi does not rely much on the interaction between the HM and its PIF-pocket for activity. This finding is in agreement with our previous report showing that mutation of the HM Glu579 to Ala had approximately the same specific activity as the wild-type enzyme (Balendran et al., 2000) . Furthermore the finding concurs with our observation that antibodies that specifically recognize the Phe residues within the HM of aPKCs did not significantly inhibit the activity of aPKCs (L.A.L.G. and R.M.B., unpublished data).
PS315 binds to the dmPDK1-z chimera in a similar manner as PS48 binds to PDK1 (Figures 5B and  5C; Table S3 ), which is reminiscent of the binding mode of the C terminus of AGC kinases to their corresponding PIF-pockets. However, the C-termini of AGC kinases are typically necessary for kinase activity, and PS48 promoted the activity of PDK1, whereas PS315 negatively influenced kinase activity. Therefore, we investigated potential molecular explanations for the divergent effects on kinase activity. We compared the crystal structure of dmPDK1 50-359 with that of PS315 in complex with the dmPDK1-z chimera. The superimposition of the two structures shows that the secondary structures match each other throughout the whole structure, suggesting that the allosteric effects that inhibit the kinase do not require major structural changes ( Figure S6 ).
The chemical structures of PS48 and PS315 differ by the presence of an additional phenyl ring ( Figure 4C ) that occupies a novel deep pocket proximal to the ATP-binding site ( Figures 5C and  5E ). This could be facilitated in the dmPDK1-z chimera by the presence of a mutation that replaces Phe157 with a shorter Leu residue. However, PKCi has a Phe residue at the same position and is also inhibited by PS315 ( Figure 4D highly flexible in solution in the fully active catalytic construct (Figures 2B and 2E) . Additionally, by entering deeper into the structure, the biphenyl group would have sterically clashed with the side chain of the highly conserved Lys111, which has a salt bridge interaction with Glu130 and the a-and b-phosphates of ATP in the active structures of protein kinases. In the PS315-bound structure, however, the ε-amino group of Lys111 is unresolved, indicating that the salt bridge that positions ATP for catalysis is affected allosterically by the binding of PS315 to the PIF-pocket.
In comparison with the PS48-bound dmPDK1 structure, residues Ser92 and Phe93 on the Gly-rich loop also underwent a conformational transition ( Figure 5F ). The Ser92 side chain rotated $90 C and lost its H bond to the ATP molecule, and Phe93 rotated $90 C around Cc toward PS315. Altogether, we conclude that the largest effect of PS315 on kinase activity is due to the disruption of the stabilizing salt bridges that position the ATP molecule optimally for catalysis.
Interestingly, PS48 and PS315 induced very different effects on key residues in the PIF-pocket that could potentially also account for their different effects on activity. An important feature of PS48 is that it tethers the C-terminal part of helix aC to the b sheet on the opposite side of the PIF-pocket by its network of interactions ). In particular, the carboxylate of PS48 stabilized residues Arg131, Lys76, and Thr148 and contacted Gln150 through a water molecule. In contrast, the carboxylate group of PS315 stabilized only the side chain of Lys131 ( Figure 5C ). However, in comparison with apo dmPDK1-z, its presence stabilizes helix aB and loop aB/aC. The binding of PS48 also allosterically stabilized the activation loop and the DFG motif. However, most residues within the activation loop are positioned identically between the PS48-and the PS315-bound structures, suggesting that the binding of PS48 or PS315 promoted similar allosteric effects on the activation loop, therefore discarding this region as a key mediator of the allosteric inhibition by PS315.
Deuterium exchange experiments with dmPDK1-z in the presence or absence of PS315 identified a single polypeptide (108-134) that was protected in the presence of this compound. This polypeptide corresponded to helix aC ( Figure S7 ). This result confirmed that the PIF-pocket was the binding site for PS315 in solution. In addition, the data obtained in solution confirm that no large conformational change in the chimera occurs upon interaction with PS315. Together with the crystal structure, these data suggest that inhibition by PS315 does not produce major conformational changes and concur with the above data indicating that PS315 subtly affected the catalytic mechanism of the enzyme.
PS315 Allosterically Affects the Interaction between the PSR and the C1 Domain
We examined the effect of PS315 on the interaction between His-PKCi D223 and the isolated N-terminal region of PKCi fused to glutathione S-transferase (GST) (GST-PSR-C1) using AlphaScreen technology . The interaction between the N-terminal region of PKCi and PKCi D223 was readily observed. Notably, PS315 displaced this interaction in a concentration-dependent manner ( Figure 6B ), suggesting that the presence of compounds in the PIF-pocket of PKCi can stabilize conformations that affect the binding of the PSR and C1 domains. We showed previously that this interaction could be displaced by HM polypeptides . The high concentration of PS315 required for displacing the allosteric interaction resembles the concentrations needed to displace the PDK1-PIFtide interaction with small compounds . In this case, the high concentrations may be required because PSRtide may stabilize a closer active conformation of helix aC, hindering the binding of PS315. Interestingly, the current finding shows that the binding of a small molecule specifically to the PIF-pocket can already produce this subtle allosteric effect, which inhibits the binding of the PSR and C1 domains to the catalytic domain.
DISCUSSION
Protein kinases play critical roles in the regulation of cellular activities. Therefore, protein kinases have evolved stringent regulation mechanisms. Notably, dysregulation of protein kinases is at the center of numerous human diseases, making protein kinases high-priority targets in drug discovery programs. However, most drug development efforts target the highly conserved ATP-binding site of protein kinases, resulting in nonselective inhibitors that target multiple protein kinases. As an alternative, there is increasing interest in the development of non-ATP-competitive regulators of protein kinases. A major impediment, however, is the lack of a complete understanding of alternative drug-binding sites on protein kinases. This work confirms that the PIF-pocket has a central role in the regulation of aPKCs by N-terminal domains and further shows that the helix aC lining the PIF-pocket is highly flexible in solution and is protected by the inhibitory N terminus but not by the PSR. We further show that PS315 allosterically inhibits aPKCs by occupying the PIF-pocket and exploiting an additional deep subpocket that is also available for PS315 interaction in a cellular environment. Moreover, we demonstrate that it is possible to mutate the PIF-pocket of PDK1 to mimic the PIF-pocket of another AGC kinase. Together, this study describes the allosteric mechanism of inhibition of aPKCs by N-terminal domains and small allosteric inhibitors targeting the PIF-pocket. Importantly, this work presents an approach using dmPDK1 50-359 as a scaffold to investigate the molecular mode of action of small allosteric molecules binding to the PIF-pocket. We envisage that an analogous approach will help to understand the allosteric mechanisms operating in other protein families and how these mechanisms can be targeted rationally for development of small-molecule allosteric agonists and antagonists. Interestingly, the mechanism of inhibition by the N-terminal domain affecting the conformation of helix aC resembles that of PKB/Akt, where the pleckstrin homology domain inhibits activity by stabilizing helix aC of the PIF-pocket in an inactive conformation (Wu et al., 2010) . Therefore, besides targeting of the PIF-pocket from the ''inside'' of the PIF-pocket, our data suggest the alternative possible development of allosteric inhibitors with a mode of action similar to those developed successfully for PKB/Akt.
Over the last 20 years, we have gained important insight into the structure of the catalytic domain of diverse protein kinases via protein crystallography. In contrast, comparably little is known about the dynamics of the catalytic domain of protein kinases in solution. With the 1 H/ 2 H exchange method, we evaluated the exposure of various regions of the protein to the solvent, providing valuable information on the dynamics of the different regions of the kinase. Notably, in the active aPKC protein, helix aC appeared to be highly exposed to solvent, more similar to the behavior of a loop region than to that of a stable a helix. The finding of the flexibility of helix aC and its stabilization by the N-terminal domains confirm the importance of helix aC in the molecular mechanism of regulation of PKCi. Helix aC forms an essential part of the PIF-pocket, a site that we characterized as a key regulatory site for the activation of a number of AGC kinases via an intramolecular interaction with a phosphorylated hydrophobic motif. Interestingly, PS315 benefits from the physiological allosteric mechanism of regulation of PKCi. Most notably, the flexibility of helix aC opened a deep tunnel and enabled PS315 to directly disrupt the conserved active site Lys-Glu pair that positions the a-and b-phosphates of ATP in all protein kinases. Together, our study provides crystallographic and dynamic structural data that demonstrate how the PIFpocket can regulate AGC kinases for allosteric activation and allosteric inhibition of kinase activity and how small molecules can exploit these allosteric mechanisms pharmacologically (Figure 7) . (C) PS315 inhibits aPKC by occupying the PIFpocket and by allosterically affecting the key residue Lys111 at the active site. PS315 binds similarly as the previously described PS48 but, in addition, occupies a deep tunnel behind helix aC that is absent in the structure of active kinases. PS315 binding displaces the C-terminal HM from the PIF-pocket and also allosterically disrupts the interaction between the PSR-C1 domains and the catalytic domain.
PKCi, like most other protein kinases within the AGC group, possesses an equivalent hydrophobic motif located C-terminal to the catalytic domain, although the phosphorylatable residue is replaced by the acidic Glu amino acid. Interestingly, the deletion of a large part of the C-terminal region that includes the hydrophobic motif (PKCi D223 DHM) only minimally affected the activity of PKCi, suggesting that this region does not have a major role in the activation of this kinase. This agrees with previous data showing that the mutation of the hydrophobic Glu to Ala did not affect the specific activity of the other atypical PKC isoform (Balendran et al., 2000) . In addition, one crystal structure of the catalytic domain of PKCi (PDB code 1ZRZ) shows that the C-terminal region has high B-factors, likely because of its labile interaction with the catalytic domain (Messerschmidt et al., 2005) . Finally, this flexibility of the C terminus corresponds with our findings that a small molecule can displace the interaction between the C-terminal hydrophobic motif and the PIF-pocket of aPKCs. Interestingly, in contrast to a role in kinase activity or activation, the C-terminal region of PKCi was protected from 1 H/ 2 H exchange by the N-terminal domains, indicating that this C-terminal extension of the catalytic core is stabilized by the N-terminal domains and may play a role in the inhibition of PKCi. Our data do not discard that the hydrophobic motif of PKCi may remain bound to the PIF-pocket of PKCi in the inactive structure of the full-length kinase. Recent structural work on the classical PKCb II isoform revealed an intramolecular interaction of the catalytic domain with the C1B domain and a crystal contact interaction with the C2 domain (Leonard et al., 2011) . We cannot foresee that any of these interactions are conserved in aPKCs because these domains do not have equivalents in aPKCs. The C1 domain from PKCb that is equivalent to the atypical C1 domain of aPKCs is the C1A domain because this is the C1 domain directly connected to the PSR ( Figure 1B ). We and others previously developed allosteric activators of protein kinase PDK1 Engel et al., 2006; Sadowsky et al., 2011; Stockman et al., 2009; Wei et al., 2010) . Previous in vitro studies demonstrated that the PIF-pocket of AGC kinases had the potential to transduce kinase inhibition. Diverse AGC kinases were partially inhibited by a non-phosphorylated HM polypeptide (Frö din et al., 2002) . A PIF-binding pocket mutant of PDK1 (PDK1[Thr148Val]) was inhibited instead of being activated (Engel et al., 2006) by the standard activating polypeptide PIFtide , and mutation of Thr148 to Cys in PDK1 and subsequent covalent modification by disulfide-trapping a small molecule fragment partially inhibited PDK1 (Sadowsky et al., 2011) . The allosteric inhibitors of aPKCs demonstrate that the PIF-pocket can be targeted with reversible small molecules to regulate AGC kinases. PKCi is a validated drug target for the treatment of lung, pancreatic, and ovarian cancers (Fields et al., 2007; Murray et al., 2011) , is upstream of hedgehog signaling in cancer (Atwood et al., 2013) , and is necessary for cancer stem cells (Regala et al., 2009) . The concentrations of PS315 that were active in vitro were similar to those concentrations that produced effects in U937 cells in culture. We cannot rule out that the effect on U937 cells may be mediated by nonspecific effects. However, we should note that an increased potency in cells is not surprising for allosteric inhibitors. Indeed, this is the case for PD098059 (Dudley et al., 1995) , a MEK-1 inhibitor that is vastly more potent in cells than in vitro on the phosphorylated active kinase because it binds preferentially to an inactive-not phosphorylated-conformation of the kinase. Together, these data justify the development of more potent derivatives of PS315 with the potential to become cancer therapeutics. A major advancement in the understanding of the mode of binding and of allosteric inhibition of PS315 was obtained from the crystallographic data. Because it was not possible to obtain crystallography data on PKCi, we tested an approach that utilized dmPDK1 50-359 as a scaffold. The data presented here demonstrate that the mutagenesis of the PIF-pocket residues of PDK1 to those of aPKC converted PDK1 into a protein that was regulated allosterically by small-molecule allosteric inhibitors of aPKCs. Moreover, similarly to dmPDK1 50-359, the dmPDK1-z chimera crystallized readily and provided the appropriate scaffold to mimic the PIF-pocket site of aPKCs. This approach may, therefore, support drug development focusing on the PIF-pocket of AGC kinases.
This work provides structural insight into the binding mode of low molecular weight allosteric inhibitors that bind to the PIFpocket of PKCi and will support the development of more potent and selective compounds for the treatment of diseases where PKCi is a validated drug target, such as cancer.
SIGNIFICANCE
The transmission of information in cell signaling often involves allosteric on-off switches. Understanding those mechanisms and how to pharmacologically modulate the switches will enable the development of innovative medicines. Protein kinases are model allosteric proteins that regulate cellular functions and are, therefore, physiologically tightly regulated. It is of interest to pharmacologically modulate the on-off switch in protein kinases for the treatment of human diseases. aPKC is a target for the treatment of cancers. We describe here that the regulation of aPKCs involves the regulation of the dynamics of the aC helix and the PIF-pocket. The small allosteric inhibitor PS315 and the N-terminal region of aPKC both act directly on the PIFpocket on-off switch. PS315, binding at the PIF-pocket, induces a displacement of the active site residue Lys111, thereby inhibiting the activity of aPKCs by allosterically affecting the catalytic mechanism of the kinase. We show here that the allosteric inhibitor profits from the dynamic nature of the regulatory PIF-pocket on-off switch. An understanding of the regulation of kinases and of the action of allosteric modulators will support drug development for aPKCs and other allosteric proteins.
EXPERIMENTAL PROCEDURES Materials
A list of materials and polypeptides used and the full description of the synthesis and characterization of PS315 is presented in Supplemental Experimental Procedures.
Expression and Purification of the Protein Kinases
Protein kinases used for crystallographic studies and 1 H/ 2 H exchange experiment were produced in Sf9 cells and purified essentially as described previously ). The dmPDK1-z plasmid was prepared by site-directed mutagenesis. Further information is detailed in Supplemental Experimental Procedures.
Protein Kinase Activity Assay
The protein kinase activity assays were performed as described previously using MBP or a variant of PSRtide where a single Ala is replaced with Ser as the aPKC substrate (Lopez-Garcia et al., 2011) and T308tide for PDK1 Engel et al., 2006) . The protein kinase and substrate mixture was preincubated with either small molecules or lipid activator. Further information is detailed in Supplemental Experimental Procedures.
H/ 2
H Exchange Assay The protein kinase sample was incubated in deuterium oxide ( 2 H 2 O) buffer at 0 C for the stated incubation times. The exchange was stopped by quenching with acid. The sample was snap-frozen and stored in liquid nitrogen prior to analysis. The labeled proteins were digested with pepsin, and the labeled derivative peptides were analyzed by liquid chromatography and mass spectrometry to determine their deuterium content. The graphics represent the number of deuterium atoms incorporated into each peptide during the stated incubation time in deuterated buffer. Each time curve is the average result of two replicates. Further information is detailed in Supplemental Experimental Procedures.
Crystallization of dmPDK1-z dmPDK1-z was crystallized by hanging drop vapor diffusion at 20 C. 1.5 ml of protein (23 mg/ml) was added to 1.5 ml of reservoir solution (1.25 M sodium citrate, 100 mM HEPES (pH 7.5), and 10 mM dithiothreitol) and 0.3 ml of 1 M ammonium sulfate. Crystals grew to a size of 300 3 300 3 80 mm within 2-3 weeks. For the PS315-bound structure, crystals were soaked for 18 hr in reservoir solution containing 1.5 mM PS315.
Data Collection, Structure Solution, and Refinement X-ray diffraction data were collected at beamline PXIII (Swiss Light Source). Data were processed and scaled using the XDS program package (Kabsch, 1993) . The structure of dmPDK1 50-359 (PDB code 3HRC) ) served as a model in molecular replacement using Phaser (McCoy et al., 2007) . PHENIX was used for refinement, including TLS protocols (Adams et al., 2010) . Coot was used for manual model building and structural analysis (Emsley and Cowtan, 2004) . Molecular graphic figures were prepared using PyMOL (DeLano, 2002) .
Thermostability Assay
The kinase thermostability assays were performed as described previously . Further information is detailed in Supplemental Experimental Procedures.
In Vivo Effects of PS315
The NF-kB luciferase reporter assay was performed as described previously . In short, U937cells were transiently transfected with a plasmid encoding luciferase under the control of NF-kB response elements (pGL4.32 [luc2P/NF-kB-RE/Hygro], Promega). The cells were serumstarved overnight and incubated in 96-well plates with PS315 or DMSO (0.25%) for 1 hr before stimulation with TNF-a (50 ng/ml, PeproTech) for 90 min. Luciferase activity was measured using Bright-Glo luciferase assay reagent (Promega) as a substrate in an EnVision multilabel reader (Perkin Elmer).
ACCESSION NUMBERS
Coordinates have been deposited in the Protein Data Bank with accession codes 4CT2 (ATP) and 4CT1 (PS315+ATP).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and three tables and can be found with this article online at http://dx.doi.org/10.1016/j.chembiol.2014.04.007.
AUTHOR CONTRIBUTIONS
H.Z. designed, performed, and analyzed molecular biology, protein purification, crystallographic, biochemical, and deuterium exchange experiments. We also characterized the PKC and PKC constructs purified in B-E. The full-length PKC had low specific activity (4.5 U/mg) and was activated 9-fold to 40 U/mg by the Figure S3 ; in the study of PKC 223 in the presence and absence of PSRtide (Fig. 3) , the identified polypeptides also comprised 81% of the PKC 223 sequence (not shown). Thermal stability of PKC 223 and PKC1-587. The thermal stability curve for PKC223 had a single phase of increasing fluorescence intensity. Under increasing incubation temperatures, PKC1-587 and PKC 223 produced distinct fluorescence emission curves, indicating that they differ in their unfolding patterns. The thermal stability curves for PKC 1-587 were more complex than those produced by PKC 223, which was expected as PKC 1-587 is a multi-domain protein. We evaluated the thermal shift and the effect of additives on the thermal stability of the PKC constructs.
As a control, we tested the effect of the non-specific ATP-competitive inhibitor staurosporine on the stability of PKC1-587 and PKC 223. Staurosporine induced an 8°C increase in the thermal stability of both proteins (Fig. 4A ).
In the established stability assay, excess of PSRtide increased the melting The result supports the crystallography finding that PS315 induces a subtle conformational change at the active site. Together the results indicate that PS315
binds to the PIF-pocket of PKC and inhibits its activity by allosterically inducing the displacement of Lys111 at the ATP-binding site. PS314 and PS315 were synthesized exactly according to Methods A to D as published previously . The E/Z configuration was assigned to the chromatographically separated isomers by comparison of the corresponding NMR spectra with those of 2Z (named PS48 herein) and 2E (E isomer of PS48) as previously described ). In the E form (PS314), the signal of the olefinic proton in 2-position is characteristically shifted downfield relative to the Z isomer PS315 (6.21 ppm vs. 5.88 ppm, respectively). Furthermore, in the Z isomer the methylene protons in positions 4 and 5 absorb at higher field than in the E isomer due to coupling with the olefinic proton (Z (PS315): 2.67-2.70 ppm (m, 2H), 2.77-2.80 ppm (m, 2H); E (PS314): 2.77-2.81 ppm (m, 2H), 3.43-3.46 ppm (m, 2H)).
Supplementary
Step 1: (E)-1-(Biphenyl-4-yl)-3-(4-chlorophenyl)prop-2-en-1-one was synthesized by a Claisen-Schmidt condensation reaction according to Method A using 122. 4, 127.3, 127.31, 128.2, 129.0, 129.1, 129.2, 129.6, 133.4, 136.4, 136.7, 139.9, 143.2, 145.7, 189 .6.
Step 2 40.2, 127.2, 127.3, 128.2, 128.6, 128.9, 129.8, 131.9, 135.4, 139.7, 139.8, 145.8, 198 .4.
Step 3: Ethyl 3-(biphenyl-4-yl)-5-(4-chlorophenyl)pent-2-enoate (E and Z) was synthesized by a Horner-Emmons reaction according to Method C using 1-(Biphenyl-4-yl)-3-(4-chlorophenyl)propan-1-one (1.5 g, 4.67 mmol), NaH (0.56 g, 14.00 mmol) and triethyl phosphonoacetate (2.89 mL, 14.47 mmol); the mixture of stereoisomers was separated using normal phase FLASH chromatography using silica gel 40 (40-63 μm) with hexane/ethyl acetate mixtures (10:1, v/v) as eluents. 32.7, 34.5, 59.9, 117.8, 127.0, 127.2, 127.3, 127.7, 128.3, 128.9, 129.9, 131.6, 139.6, 139.9, 140.2, 141.9, 146.7, 158.4, 166. 41.8, 59.9, 118.0, 126.6, 127.0, 127.3, 127.8, 128.5, 128.7, 129.7, 131.8, 138.4, 139.2, 140.6, 157.5, 165 .9.
Step 4: (E)-3-(Biphenyl-4-yl)-5-(4-chlorophenyl)pent-2-enoic acid, (PS314 34.6, 116.7, 127.1, 127.2, 127.4, 127.8, 128.5, 128.9, 131.8, 139.4, 139.7, 140.1, 142.4, 161.6, 171 .2. Hz, 2H), 7.44 (t, J = 7.9 Hz, 2H), 7.58 (d, J = 7.58 Hz, 2H), 7.61 (t, J = 7.9 Hz, 2H); 126.8, 127.1, 127.5, 127.8, 128.6, 128.7, 129.7, 132.0, 137.7, 138.9, 139.0, 141.4, 161.0, 166.5 .
Expression and purification of the protein kinases
The dmPDK1- 50-359 protein used for crystallography studies was prepared exactly as previously described for dmPDK1 50-359 (Hindie et al., 2009) . In short, dmPDK1-
